Roche's $8 billion InterMune acquisition, disclosed a decade ago, is now being handed to a specialty pharmaceutical company.

Helmed by Roche alums, Newleos Therapeutics is taking over four drugs dropped from the Swiss pharma’s pipeline in early 2024.

Roche announced this morning that its head of pharmaceuticals, Bill Anderson, is leaving the company to pursue "other opportunities" after four years in the role. Anderson will be replaced in the ...

Swiss pharma giant Roche Holding AG RHHBY posted better-than-expected 2024 results and provided an encouraging outlook for ...

Over the past nine years, patients with spinal muscular atrophy have seen the number of FDA-approved treatment options for ...

If anything, the gap understates the gulf between the soft-spoken, beetle-browed Hoffmann, who is the great-grandson of Fritz Hoffmann-La Roche, founder of pharmaceuticals group Roche, and the ...

Roche projects mid-single digit group sales growth in 2025, with core EPS growth in the high-single digit range. The company expects a CHF1.2 billion impact from the loss of exclusivity but aims to ...

Roche tells Andrew McConaghie that inaccurate reports of its price have distorted the debate. Just as US pharma is once again ... price cuts it offers to the Department of Health bring it down ...

As for Susvimo, Roche’s pharma chief Teresa Graham said on an earnings call last week that approximately 100 implants were completed in 2024. “In this stage of the launch, it’s all about ...

CNBC's Angelica Peebles talks to Roche Pharma CEO Teresa Graham discusses why we're still in the early stages of the obesity drug race. Moss Landing fire: One of the world’s largest battery ...